PREDICTING VACCINE EFFICACY
The present invention provides methods for evaluating a vaccine, combinations of tests and reaction mixtures that can be used as part of such methods, and collections of results comprising results obtained from such methods. The methods, combinations, and collections are useful for determining whether a vaccine is effective and, for example, for comparing the efficacy of different vaccines.
1 . A method for evaluating a vaccine in a subject comprising determining in the subject the activity of at least two genes selected from the group consisting of genes associated with the proimflammatory state and genes associated with induction of a cellular immune response in the subject, wherein a collective result of the activity of at least two genes is indicative of the efficacy of the vaccine.
2 . The method of claim 1 , wherein determining the activity of at least two genes comprises determining gene transcription level, gene translation level, protein activation level, or a combination thereof.
3 . The method of claim 1 , wherein genes associated with the proimflammatory state include IL8, MMP9, IL1, IL2, IL4, IL6, IL10, IL12B, IL18, TNF, IFN-γ, FGF1, CD63, CTGF, CCL1, NFkB1, STAT1, CSF1, MCP, MCP-1RB, IRF-1, and HSGPCRIN8.
4 . The method of claim 1 , wherein genes associated with induction of a cellular immune response include IFN-γ, STAT1, IL10, CD11b, NFkb, IL12, IRF-1, CYP1B1, ICAM1, CYP1A1, TP53, IL1B, IL15, CD14, LTA, CD4, NOS2A, CSF2, CYP1A2, PTGS2, CASP9, CD8A, MYC, PTPRC, NFkB1, CASP3, IL23A, and SCIN.
5 . The method of claim 1 , wherein a decrease in the activity of a gene associated with the proimflammatory state is indicative of the efficacy of the vaccine.
6 . The method of claim 1 , wherein an increase in the activity of a gene associated with the induction of a cellular immune response is indicative of the efficacy of the vaccine.
7 . The method of claim 1 , wherein a decrease in the activity of a gene associated with the proimflammatory state and an increase in the activity of a gene associated with the induction of a cellular immune response is indicative of the efficacy of the vaccine.
8 . The method of claim 1 , wherein a decrease in the activity of IL8, MMP9, IL1, IL2, IL4, IL6, IL10, IL12B, IL18, TNF, IFN-γ, FGF1, CD63, CTGF, CCL1, NFkB1, STAT1, CSF1, MCP, MCP-1RB, IRF-1, and HSGPCRIN8 is indicative of the efficacy of the vaccine.
9 . The method of claim 1 , wherein an increase in the activity of IFN-γ, STAT1, IL-10, CD11b, NFkb, IL-12, IRF-1, CYP1B1, ICAM1, CYP1A1, TP53, IL1B, IL15, CD14, LTA, CD4, NOS2A, CSF2, CYP1A2, PTGS2, CASP9, CD8A, MYC, PTPRC, NFkB1, CASP3, IL23A, and SCIN is indicative of the efficacy of the vaccine.
10 . The method of claim 1 comprising determining the activity of at least three, four, or five genes.
11 . The method of claim 1 , further comprising vaccinating the subject with the vaccine prior to said evaluating.
12 . The method of claim 1 , further comprising obtaining a sample from said subject prior to said evaluating.
13 . The method of claim 12 , wherein the sample is a blood sample.
14 . A combination of tests useful for predicting whether a vaccine is effective comprising
a first test for the activity of a first gene and
a second test for the activity of a second gene,
wherein the first gene and the second gene are selected from the group consisting of genes associated with the proimflammatory state and genes associated with induction of a cellular immune response.
15 . The combination of tests of claim 14 , wherein the first gene or the second gene is selected from the group consisting of IL8, MMP9, IFN-γ, STAT1, IL10, CD11b, NFkB1, IRF-1, IL6, TGFbeta, IL4, CSF1, CCR2, GZMA, GZMB, TNFalpha, FGF1, PD1, CCL4, Perforin, MCP1, IL18, and CXCR3.
16 . The combination of tests of claim 14 , wherein the activity of a first gene and a second gene comprises gene transcription level, gene translation level, or protein activation level, or a combination thereof.
17 . The combination of tests of claim 14 further comprising a third test for the activity of a third gene, wherein the third gene is selected from the group consisting of genes associated with the proimflammatory state and genes associated with induction of a cellular immune response.
18 . The combination of tests of claim 14 further comprising a third test for the proliferation of T-cells.
19 . A method of providing useful information for evaluating whether a vaccine is effective comprising
determining the activity of a first set of genes and
providing the activity of the first set of genes to an entity that analyzes the activity and provides an evaluation of the vaccine,
wherein the first set of genes comprises at least two genes selected from the group consisting of genes associated with proimflammatory state and genes associated with induction of a cellular immune response.
20 . The method of claim 19 , wherein the first set of genes are selected from the group consisting of IL8, MMP9, IFN-γ, STAT1, IL10, CD11b, NFkB1, IRF-1, IL6, TGFbeta, IL4, CSF1, CCR2, GZMA, GZMB, TNFalpha, FGF1, PD1, CCL4, Perforin, MCP1, IL18, and CXCR3.
21 . The method of claim 19 , wherein the activity of the first set of genes are provided in a format compatible with a computer algorithm used by the entity for analysis.
22 . The method of claim 19 , wherein the first set of genes are at least three genes selected from the group consisting of IL8, MMP9, IFN-γ, STAT1, IL10, CD11b, NFkB1, IRF-1, IL6, TGFbeta, IL4, CSF1, CCR2, GZMA, GZMB, TNFalpha, FGF1, PD1, CCL4, Perforin, MCP1, IL18, and CXCR3.
23 . The method of claim 19 , wherein the first set of genes are at least four genes selected from the group consisting of IL8, MMP9, IFN-γ, STAT1, IL10, CD11b, NFkB1, IRF-1, IL6, TGFbeta, IL4, CSF1, CCR2, GZMA, GZMB, TNFalpha, FGF1, PD1, CCL4, Perforin, MCP1, IL18, and CXCR3.
24 . A collection of results useful for evaluating whether a vaccine is effective comprising values for the activity of a first set of genes selected from the group consisting of genes associated with proinflammatory state and genes associated with induction of a cellular immune response, wherein the first set of genes comprises at least two genes.
25 . The collection of results of claim 24 , wherein the first set of genes are selected from the group consisting of IL8, MMP9, IFN-γ, STAT1, IL10, CD11b, NFkB1, IRF-1, IL6, TGFbeta, IL4, CSF1, CCR2, GZMA, GZMB, TNFalpha, FGF1, PD1, CCL4, Perforin, MCP1, IL18, and CXCR3.
26 . The collection of results of claim 24 , wherein the first set of genes comprises at least three, four or five genes.
27 . The collection of results of claim 24 , wherein said values are in a format compatible with a computer algorithm for analyzing the results and providing an evaluation of the vaccine.
28 . A collection of nucleotides useful for determining the activity of a set of genes selected from the group consisting of genes associated with proimflammatory state and genes associated with induction of a cellular immune response, wherein the set of genes comprises at least two genes.
29 . The collection of claim 28 , wherein the nucleotides can be useful for determining the activity of a set of genes in two or more species.
30 . The collection of claim 28 , wherein the nucleotides are probes for determining the gene expression level or gene translation level of the set of genes.
31 . The collection of claim 28 , wherein the nucleotides are probes for determining the gene expression level or gene translation level of the set of genes and wherein the nucleotides are provided on a solid support.
32 . The collection of claim 28 , wherein the nucleotides are primers for determining the gene expression level or gene translation level of the set of genes.
33 . A reaction mixture comprising primers or probes useful for determining the activity of a set of genes selected from the group consisting of genes associated with proimflammatory state and genes associated with induction of a cellular immune response, wherein the set of genes comprises at least two genes.
34 . The reaction mixture of claim 33 comprising amplified products corresponding to the set of genes.
35 . The reaction mixture of claim 33 comprising primers and probes useful for determining the activity of the set of genes.
36 . The reaction mixture of claim 33 , wherein the set of genes comprises at least three, four, or five genes.
37 . The reaction mixture of claim 33 , wherein the set of genes are selected from the group consisting of IL8, MMP9, IFN-γ, STAT1, IL10, CD11b, NFkB1, IRF-1, IL6, TGFbeta, IL4, CSF1, CCR2, GZMA, GZMB, TNFalpha, FGF1, PD1, CCL4, Perforin, MCP1, IL18, and CXCR3.